研究者詳細 - 髙橋　直人

研究等業績 - その他 - 髙橋　直人

分割表示 237 件中 41 - 60 件目／全件表示 >>

糖尿病性腎病腎組織におけるToll-like receptor 4発現と腎予後の検討

齋藤綾乃, 阿部史人, 齋藤雅也, 金澤達郎, 橋本眞子, 坂口舞, 中山隆弘, 大谷浩, 澤村昌人, 奥山慎, 政井理恵, 高橋直人

日本腎臓学会誌 ( (一社)日本腎臓学会 ) 66 ( 4 ) 673 - 673 2024年06月

Development and evaluation of a rapid one-step high sensitivity real-time quantitative PCR system for minor BCR-ABL (e1a2) test in Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)

Hidaka M.

Japanese Journal of Clinical Oncology ( Japanese Journal of Clinical Oncology ) 54 ( 2 ) 153 - 159 2024年02月

OBJECTIVE: Minimal residual disease assessment of BCR-ABL messenger ribonucleic acid levels is crucial in Philadelphia chromosome-positive acute lymphoblastic leukemia for prognosis and treatment planning. However, accurately quantifying minor BCR-ABL transcripts, which comprise 70% of Philadelphia chromosome-positive acute lymphoblastic leukemia cases, lacks a national-approved method. METHODS: We developed the "Otsuka" minor BCR-ABLmessenger ribonucleic acid assay kit with exceptional precision (0.00151%). Minor BCR-ABL messenger ribonucleic acid levels were analyzed in 175 adults, 36 children with acute lymphoblastic leukemia and 25 healthy individuals to evaluate the kit's performance. RESULTS: The "Otsuka" kit showed high concordance with a commonly used chimeric gene screening method, indicating reliable detection of positive cases. Quantitative results demonstrated a robust correlation with both a laboratory-developed test and a diagnostic research product. The "Otsuka" kit performs comparably or even surpass to conventional products, providing valuable insights into Philadelphia chromosome-positive acute lymphoblastic leukemia pathology. CONCLUSIONS: The 'Otsuka" minor BCR-ABL messenger ribonucleic acid assay kit exhibits excellent performance in quantifying minor BCR-ABL transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia patients. Our results align well with established screening methods and show a strong correlation with laboratory-developed tests and diagnostic research products. The "Otsuka" kit holds great promise as a valuable tool for understanding Philadelphia chromosome-positive acute lymphoblastic leukemia pathology and guiding effective treatment strategies.

DOI PubMed

7．慢性骨髄性白血病の治療の進歩

髙橋直人

日本内科学会雑誌 ( 一般社団法人日本内科学会 ) 113 ( Suppl ) 120a - 120a 2024年02月

DOI CiNii Research

Prognostic impact of peripheral blood WT1 mRNA dynamics in patients with acute myeloid leukemia treated with venetoclax combination therapy

Sato H.

International Journal of Clinical Oncology ( International Journal of Clinical Oncology ) 29 ( 4 ) 481 - 492 2024年

DOI

クローン病の治療中に発症し臍帯血移植が奏効した化学療法抵抗性γδ型肝脾T細胞リンパ腫

齊藤暉人, 奈良美保, 藤島崇嗣, 黒木航, 山下鷹也, 小林敬宏, 池田翔, 北舘明宏, 亀岡吉弘, 高橋直人

臨床血液 ( 一般社団法人日本血液学会 ) 65 ( 1 ) 41 - 46 2024年

症例21歳男性。Crohn病のためinfliximab，azathioprineによる治療を受けていたが6年後，発熱，LDH 2,473 U/l，血小板低下，肝脾腫を認めた。骨髄生検と肝生検でCD4，CD56，TCRγδ陽性，CD8陰性の異型細胞を認め，肝脾T細胞リンパ腫（hepatosplenic T-cell lymphoma, HSTCL）と診断した。CHOP療法，dose-adjusted-EPOCH療法後に非寛解状態で骨髄破壊的前処置による臍帯血移植を行った。退院前造影CTで肝脾腫縮小，LDH 165 U/l，血小板18万/µlと正常化を認めday117に退院した。HSTCLは脾臓内のVδ1遺伝子変異を伴う未熟なγδT細胞をカウンターパートとする腫瘍であり，発症には免疫不全状態の関与が示唆されており予後は不良である。Azathioprineで治療された炎症性腸疾患患者はリンパ増殖性疾患リスクが増加することが知られており，本症例もCrohn病に対する免疫抑制剤の使用により腸管上皮に存在するγδ細胞が悪性化した可能性がある。化学療法抵抗性であったが早期の臍帯血移植で寛解を達成し，長期予後を期待している。

DOI PubMed CiNii Research

A practice-oriented genome-profiling study for acute myeloid leukemia using the novel HANDLE system: HM-screen-JAPAN02

Arai H.

International Journal of Hematology ( International Journal of Hematology ) 121 ( 3 ) 378 - 387 2024年

DOI

JSH practical guidelines for hematological malignancies, 2023: leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN)

Takahashi N.

International Journal of Hematology ( International Journal of Hematology ) 121 ( 1 ) 5 - 38 2024年

DOI

Overexposure to venetoclax is associated with prolonged-duration of neutropenia during venetoclax and azacitidine therapy in Japanese patients with acute myeloid leukemia

Kobayashi Takahiro, Honami Sato, Miura Masatomo, Fukushi Yayoi, Kuroki Wataru, Ito Fumiko, Teshima Kazuaki, Watanabe Atsushi, Fujishima Naohito, Kobayashi Isuzu, Kameoka Yoshihiro, Takahashi Naoto

Cancer Chemotherapy and Pharmacology ( Springer Nature ) 2024年

CiNii Research

Case report: Three characteristics of tyrosine kinase inhibitor-associated cerebrovascular stenosis. High threshold for infarction, atypical infarct area, and vascular recoverability under the use of ponatinib

Hanazono A.

Frontiers in Stroke ( Frontiers in Stroke ) 3 2024年

DOI

チロシンキナーゼ阻害剤の薬物血中濃度モニタリングを施行した小児白血病

田村真一, 飛鳥暉晶, 内藤優樹, 友安千紘, 矢野未央, 石田宏之, 岡野創造, 三浦昌朋, 高橋直人, 黒田啓史

近畿小児科学会プログラム・抄録集 37th 2024年

J-GLOBAL

Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial

Cortes J.E.

Future Oncology ( Future Oncology ) 18 ( 38 ) 4161 - 4170 2023年12月

DOI

経口薬で白血病を治す－CMLに対する分子標的療法の挑戦

高橋直人

日本医療薬学会年会講演要旨集 ( 一般社団法人日本医療薬学会 ) 33 ( 0 ) 4 - 4 2023年11月

DOI CiNii Research

t(4;14)陽性多発性骨髄腫に対するMMSET阻害剤

松岡紗恵, 菊池次郎, 長田直希, 窪田浩一, 喜久里貢, 小山裕雄, 菊地正樹, 安井寛, 池田翔, 高橋直人, 梅原崇史, 仲宗根秀樹, 古川雄祐

日本血液学会学術集会 ( (一社)日本血液学会 ) 85回 44 - 44 2023年10月

AMLのVEN/AZA治療におけるベネトクラクスの血中濃度と好中球減少症との関連

小林敬宏, 佐藤保奈実, 三浦昌朋, 福司弥生, 藤田菜々子, 黒木航, 伊藤史子, 手島和暁, 渡部敦, 藤島直仁, 高橋直人

日本血液学会学術集会 ( (一社)日本血液学会 ) 85回 377 - 377 2023年10月

Clinical Course of a Rare Epstein-Barr Virus-Associated Smooth Muscle Tumor and Its Genomic Analysis

Miyahara J.

Case Reports in Oncology ( Case Reports in Oncology ) 16 ( 1 ) 577 - 584 2023年08月

Epstein-Barr virus (EBV) can rarely induce smooth muscle tumors (SMTs). A 20-year-old female patient underwent kidney transplantation for renal failure. Since then, she has been treated with immunosuppressants, including a calcineurin inhibitor, tacrolimus, and prednisolone, owing to the immunological rejection. Three years later, she developed large liver tumors (diameter >5 cm) and multiple small lung tumors that were identified as EBV-SMTs based on the results of liver biopsy/histopathology. No intervention was performed except for the addition of a mammalian target of the rapamycin inhibitor, everolimus, which inhibits both immune reaction and SMT growth. Finally, after 8 years, the transplanted kidney became nonfunctional, and immunosuppressant administration became unnecessary as urinary dialysis was started. Under these circumstances, SMT growth was observed despite the absence of immunosuppressant administration. Three months after the cessation of the immunosuppressants, EBV-SMTs in the liver and lungs shrank slightly. To the best of our knowledge, this is the first report on the genomic profile of this rare tumor. The clinical course of our patient indicates that EBV can induce SMTs, and immunological suppression of EBV may inhibit the activity of these tumors.

DOI PubMed

Acute Myeloid Leukemia Harboring the t(16;21)(p11;q22) Translocation Treated With Venetoclax Plus Azacitidine After Cord Blood Transplantation.

Kazuaki Teshima, Sho Ikeda, Ko Abe, Masahiro Yamada, Naoto Takahashi

Cureus 15 ( 7 ) e42215 2023年07月

A 62-year-old female was diagnosed with acute myeloid leukemia (AML) with t(16;21)(p11;q22). She achieved complete hematological remission after induction therapy and underwent umbilical cord blood stem cell transplantation (CBT). At 150 days after the CBT, a bone marrow examination revealed relapse. We treated the patient with venetoclax plus azacitidine as salvage therapy. After five cycles of venetoclax and azacitidine therapy, the patient died due to disease progression. The prognosis of AML with t(16;21)(p11;q22) is very poor owing to the high rate of early relapse even after hematopoietic stem cell transplantation. Therefore, a novel therapeutic approach is required to improve patient outcomes.

DOI PubMed

保存期CKDにおけるESA初期治療抵抗性と予後に関する検討

金澤達郎, 齋藤雅也, 齋藤綾乃, 阿部史人, 加賀一, 高橋直人

日本腎臓学会誌 ( (一社)日本腎臓学会 ) 65 ( 3 ) 294 - 294 2023年05月

糖尿病性腎臓病腎組織におけるToll-like receptor 4発現と病理学的検討

齋藤綾乃, 阿部史人, 齋藤雅也, 加賀一, 金澤達郎, 高橋直人

日本腎臓学会誌 ( (一社)日本腎臓学会 ) 65 ( 3 ) 317 - 317 2023年05月

c-FOSはIKZF1転写活性化複合体の重要な構成要素であり、多発性骨髄腫におけるレナリドマイド耐性を誘導する(c-FOS is an integral component of the IKZF1 transactivator complex and mediates lenalidomide resistance in multiple myeloma)

長田直希, 菊池次郎, 安井寛, 池田翔, 松岡紗恵, 高橋直人, 古川雄祐

International Journal of Myeloma ( (一社)日本骨髄腫学会 ) 13 ( 3 ) 136 - 136 2023年05月

Outcomes of adult patients with early T-cell precursor (ETP) acute lymphoblastic leukemia/lymphoma (ALL) and non-ETP T-ALL

Onishi Y.